MedPath

Role of combination antifungal therapy (Liposomal Amphotericin B and Posaconazole) in Mucormycosis

Phase 2
Conditions
Health Condition 1: B46- Zygomycosis
Registration Number
CTRI/2021/07/034907
Lead Sponsor
AIIMS Department of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All patients aged 18 years or more, newly diagnosed probable (clinical and radiological) or proven invasive mucormycosis will be included.

Exclusion Criteria

1 Patients not willing to consent.

2 Patients with more than 5 days of primary antifungal therapy

3 Patients unable to receive enteral medications.

4 Co-existing conditions precluding the use of both Amphotericin B or Posaconazole

a Liposomal Amphotericin B â?? history of hypersensitivity

b Posaconazole â?? H/o hypersensitivity (other azoles), Concurrent drugs (Sirolimus: can result in sirolimus toxicity; CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of Torsades de Pointes; HMG-CoA Reductase Inhibitors Primarily Metabolized Through CYP3A4: can lead to rhabdomyolysis, Ergot alkaloids: can result in ergotism drug interactions); Transaminitis ( AST or ALT >5 times ULN)

5 Patients who are critically ill/ hemodynamic instability

6 Patients with active moderate and severe COVID19 illness at the time of recruitment

7 Breastfeeding/ pregnancy

8 Patient enrolled in other ongoing prospective drug trials for IM

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Complete or partial response at week 3Timepoint: 3 weeks
Secondary Outcome Measures
NameTimeMethod
1.Complete response at week 6 and week 12 <br/ ><br>Timepoint: 6 weeks, 12 weeks;3.Reduction in all-cause mortalityTimepoint: 12 months; <br/ ><br>2.Increased survival at week 12, 6 months and 12 months. <br/ ><br> <br/ ><br>Timepoint: 3, 6 and 12 months
© Copyright 2025. All Rights Reserved by MedPath